Staging liver fibrosis by using liver-enhancement ratio of gadoxetic acid-enhanced MR imaging: Comparison with aspartate aminotransferase-to-platelet ratio index

Magnetic Resonance Imaging

Volumn 29, Issue 8, 2011, Pages 1047-1052

  Motosugi, Utaroh ^a   Ichikawa, Tomoaki ^a   Oguri, Mitsuhiko ^a   Sano, Katsuhiro ^a   Sou, Hironobu ^a   Muhi, Ali ^a   Matsuda, Masanori ^a   Fujii, Hideki ^a   Enomoto, Nobuyuki ^a   Araki, Tsutomu ^a  

^a UNIVERSITY OF YAMANASHI   (Japan)

Author keywords

Cirrhosis; Gadoxetic acid; Liver; MR imaging

Indexed keywords

ASPARTATE AMINOTRANSFERASE; GADOXETIC ACID;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE TO PLATELET RATIO INDEX; CLINICAL ASSESSMENT; CONTRAST ENHANCEMENT; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISEASE MARKER; DISEASE SEVERITY; HUMAN; LIVER BIOPSY; LIVER ENHANCEMENT RATIO; LIVER EXAMINATION; LIVER FIBROSIS; LIVER SPLEEN CONTRAST RATIO; MAJOR CLINICAL STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SPLEEN INDEX; STAGING; THROMBOCYTE COUNT;

ADULT; AGED; AGED, 80 AND OVER; AREA UNDER CURVE; ASPARTATE AMINOTRANSFERASES; BLOOD PLATELETS; CONTRAST MEDIA; FIBROSIS; GADOLINIUM DTPA; HUMANS; LIVER; LIVER CIRRHOSIS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; ROC CURVE;

EID: 80052643349     PISSN: 0730725X     EISSN: 18735894     Source Type: Journal    
DOI: 10.1016/j.mri.2011.05.007     Document Type: Article

References (34)

1. Perrillo R.P. The role of liver biopsy in hepatitis C. Hepatology 1997, 26:57S-61S.
2. Yoshida H., Shiratori Y., Moriyama M., Arakawa Y., Ide T., Sata M., et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med 1999, 131:174-181.
3. Tsukuma H., Hiyama T., Tanaka S., Nakao M., Yabuuchi T., Kitamura T., et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993, 328:1797-1801.
4. Glaser K.J., Felmlee J.P., Manduca A., Ehman R.L. Shear stiffness estimation using intravoxel phase dispersion in magnetic resonance elastography. Magn Reson Med 2003, 50:1256-1265.
5. Rouviere O., Yin M., Dresner M.A., Rossman P.J., Burgart L.J., Fidler J.L., et al. MR elastography of the liver: preliminary results. Radiology 2006, 240:440-448.
6. Talwalkar J.A., Yin M., Fidler J.L., Sanderson S.O., Kamath P.S., Ehman R.L. Magnetic resonance imaging of hepatic fibrosis: emerging clinical applications. Hepatology 2008, 47:332-342.
7. Motosugi U., Ichikawa T., Sou H., Sano K., Muhi A., Koshiishi T., et al. Magnetic resonance elastography of the liver: Preliminary results and estimation of interrater reliability. Jpn J Radiol 2010, 28:623-627.
8. Huwart L., Sempoux C., Salameh N., Jamart J., Annet L., Sinkus R., et al. Liver fibrosis: noninvasive assessment with MR elastography versus aspartate aminotransferase-to-platelet ratio index. Radiology 2007, 245:458-466.
9. Annet L., Peeters F., Abarca-Quinones J., Leclercq I., Moulin P., Van Beers B.E. Assessment of diffusion-weighted MR imaging in liver fibrosis. J Magn Reson Imaging 2007, 25:122-128.
10. Hagiwara M., Rusinek H., Lee V.S., Losada M., Bannan M.A., Krinsky G.A., et al. Advanced liver fibrosis: diagnosis with 3D whole-liver perfusion MR imaging-initial experience. Radiology 2008, 246:926-934.
11. Wai C.T., Greenson J.K., Fontana R.J., Kalbfleisch J.D., Marrero J.A., Conjeevaram H.S., et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003, 38:518-526.
12. Paggi S., Colli A., Fraquelli M., Vigano M., Del Poggio P., Facciotto C., et al. A non-invasive algorithm accurately predicts advanced fibrosis in hepatitis C: a comparison using histology with internal-external validation. J Hepatol 2008, 49:564-571.
13. Castera L., Vergniol J., Foucher J., Le Bail B., Chanteloup E., Haaser M., et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005, 128:343-350.
14. Ichikawa T., Saito K., Yoshioka N., Tanimoto A., Gokan T., Takehara Y., et al. Detection and characterization of focal liver lesions: a Japanese Phase III, multicenter comparison between gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced computed tomography predominantly in patients with hepatocellular carcinoma and chronic liver disease. Invest Radiol 2010, 45:133-141.
15. Reimer P., Rummeny E.J., Daldrup H.E., Hesse T., Balzer T., Tombach B., et al. Enhancement characteristics of liver metastases, hepatocellular carcinomas, and hemangiomas with Gd-EOB-DTPA: preliminary results with dynamic MR imaging. Euro Radiol 1997, 7:275-280.
16. Hammerstingl R., Huppertz A., Breuer J., Balzer T., Blakeborough A., Carter R., et al. Diagnostic efficacy of gadoxetic acid (Primovist)-enhanced MRI and spiral CT for a therapeutic strategy: comparison with intraoperative and histopathologic findings in focal liver lesions. Euro Radiol 2008, 18:457-467.
17. Bluemke D.A., Sahani D., Amendola M., Balzer T., Breuer J., Brown J.J., et al. Efficacy and safety of MR imaging with liver-specific contrast agent: U.S. multicenter phase III study. Radiology 2005, 237:89-98.
18. Huppertz A., Balzer T., Blakeborough A., Breuer J., Giovagnoni A., Heinz-Peer G., et al. Improved detection of focal liver lesions at MR imaging: multicenter comparison of gadoxetic acid-enhanced MR images with intraoperative findings. Radiology 2004, 230:266-275.
19. Vogl T.J., Kummel S., Hammerstingl R., Schellenbeck M., Schumacher G., Balzer T., et al. Liver tumors: comparison of MR imaging with Gd-EOB-DTPA and Gd-DTPA. Radiology 1996, 200:59-67.
20. Motosugi U., Ichikawa T., Sou H., Sano K., Tominaga L., Kitamura T., et al. Liver parenchymal enhancement of hepatocyte-phase images in Gd-EOB-DTPA-enhanced MR imaging: which biological markers of the liver function affect the enhancement?. J Magn Reson Imaging 2009, 30:1042-1046.
21. Watanabe H., Kanematsu M., Goshima S., Kondo H., Onozuka M., Moriyama N., et al. Staging hepatic fibrosis: comparison of gadoxetate disodium-enhanced and diffusion-weighted MR imaging-preliminary observations. Radiology 2011, 259:142-150.
22. Suzuki K., Kirikoshi H., Yoneda M., Mawatari H., Fujita K., Nozaki Y., et al. Measurement of spleen volume is useful for distinguishing between simple steatosis and early-stage non-alcoholic steatohepatitis. Hepatol Res 2010, 40:693-700.
23. Watanabe S., Hosomi N., Kitade Y., Kurokohchi K., Arima K., Kawabata H., et al. Assessment of the presence and severity of esophagogastric varices by splenic index in patients with liver cirrhosis. J Comput Assist Tomogr 2000, 24:788-794.
24. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology 1994, 20:15-20.
25. Lackner C., Struber G., Liegl B., Leibl S., Ofner P., Bankuti C., et al. Comparison and validation of simple noninvasive tests for prediction of fibrosis in chronic hepatitis C. Hepatology 2005, 41:1376-1382.
26. Fujii H., Enomoto M., Fukushima W., Ohfuji S., Mori M., Kobayashi S., et al. Noninvasive laboratory tests proposed for predicting cirrhosis in patients with chronic hepatitis C are also useful in patients with non-alcoholic steatohepatitis. J Gastroenterol 2009, 44:608-614.
27. Cheung R.C., Currie S., Shen H., Bini E.J., Ho S.B., Anand B.S., et al. Can we predict the degree of fibrosis in chronic hepatitis C patients using routine blood tests in our daily practice?. J Clin Gastroenterol 2008, 42:827-834.
28. Sebastiani G., Vario A., Guido M., Alberti A. Performance of noninvasive markers for liver fibrosis is reduced in chronic hepatitis C with normal transaminases. J Viral Hepat 2008, 15:212-218.
29. Asbach P., Klatt D., Schlosser B., Biermer M., Muche M., Rieger A., et al. Viscoelasticity-based staging of hepatic fibrosis with multifrequency MR elastography. Radiology 2010, 257:80-86.
30. Obara N., Ueno Y., Fukushima K., Nakagome Y., Kakazu E., Kimura O., et al. Transient elastography for measurement of liver stiffness measurement can detect early significant hepatic fibrosis in Japanese patients with viral and nonviral liver diseases. J Gastroenterol 2008, 43:720-728.
31. Foucher J., Chanteloup E., Vergniol J., Castera L., Le Bail B., Adhoute X., et al. Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. Gut 2006, 55:403-408.
32. Goertz R.S., Zopf Y., Jugl V., Heide R., Janson C., Strobel D., et al. Measurement of liver elasticity with acoustic radiation force impulse (ARFI) technology: an alternative noninvasive method for staging liver fibrosis in viral hepatitis. Ultraschall Med 2010, 31:151-155.
33. Takahashi H., Ono N., Eguchi Y., Eguchi T., Kitajima Y., Kawaguchi Y., et al. Evaluation of acoustic radiation force impulse elastography for fibrosis staging of chronic liver disease: a pilot study. Liver Int 2010, 30:538-545.
34. Tschirch F.T., Struwe A., Petrowsky H., Kakales I., Marincek B., Weishaupt D. Contrast-enhanced MR cholangiography with Gd-EOB-DTPA in patients with liver cirrhosis: visualization of the biliary ducts in comparison with patients with normal liver parenchyma. Euro Radiol 2008, 18:1577-1586.